Purchase this article with an account.
J.R. Wittpenn, B. Schechter; Efficacy of Cyclosporine a for the Treatment of Ocular Rosacea . Invest. Ophthalmol. Vis. Sci. 2005;46(13):2846.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To compare the efficacy of cyclosporine A (Restasis, Allergan) with an artificial tear solution (Refresh Endura, Allergan) for the treatment of rosacea–associated lid and corneal changes. Methods: Double–masked clinical trial. Patients (n=20) with rosacea–associated lid and corneal changes were enrolled after any active infections were treated with lid scrubs and antibiotics. Once the infection was clinically controlled, patients were randomized to CsA or artificial tears for 3 months. All patients were withdrawn from oral doxycycline for at least 2 weeks and patients with lid defects and lagophthalmos were excluded. Results: Topical CsA produced a statistically significant increase in Schirmer’s (with anesthesia) scores of 2.9 mm after 3 months of treatment (P=.002). Conversely, Schirmer’s scores worsened significantly in the tears group, with a mean decrease of 6.4 mm (P=.029). Similarly, the mean TBUT score also significantly improved in the CsA–treated patients (a mean increase of 3.0 sec, P=.002), but worsened in the control group (a mean decrease of 1.0 sec, P=.319). Moreover, CsA provided significantly greater improvement in OSDI scores than did tears (mean reduction of 9.0 with CsA versus a mean increase of 2.7 with tears, P=.003). Conclusions: Topical cyclosporine A is superior to artificial tears for the treatment of rosacea–associated lid and corneal changes. These findings are currently being confirmed in a larger ongoing clinical trial.
This PDF is available to Subscribers Only